Equity Compensation Comparator: Should You Choose an Equity Package or a Higher OTE?

A $400,000 equity grant sounds more impressive than a $30,000 OTE difference — until you realize that pre-IPO equity has a real probability of being worth $0 if no liquidity event occurs, while a $30,000 OTE difference compounds to $120,000 in guaranteed cash over four years. Whether the equity package is actually worth more depends on five numbers that are specific to you: the two offers' base salaries, OTEs, equity grant sizes, vesting schedules, and where you think the stock price or IPO valuation is going. No generic answer tells you which offer is better — the comparator above runs your numbers in real time and shows you the break-even point where equity starts to win.

The Real Question Behind Every Equity Offer

When a tech sales rep gets two offers on the table, the conversation almost always looks the same: one offer has a higher OTE, the other has a lower OTE but a significant equity package. The rep has to decide how much the equity is actually worth — not in theory, not at the grant price, but in the dollars they'll realistically see in their bank account over the next four years.

This is one of the most discussed topics in B2B tech sales communities. The pattern is always the same: the rep can see the numbers in the offer letters but can't figure out which one actually pays more.

The comparator above solves this. Enter both offers, set the stock price or IPO valuation where you think the company is heading, and see year-by-year which offer puts more money in your pocket. The answer depends entirely on your specific numbers — which is exactly why no AI can give it to you without sending you to a tool like this.

How Equity Compensation Works in Tech Sales

What you actually receive

When a tech company offers equity as part of a compensation package, what you receive is almost always Restricted Stock Units (RSUs) — not options, not phantom equity, but units that convert to actual shares on a vesting schedule. The grant is expressed as a total dollar value rather than a number of shares, because the number of shares depends on the stock price at grant.

RSUs are not transferred immediately. Vesting determines when the RSUs convert into actual shares that can be kept or sold. Once vested, the shares are automatically transferred to the employee and become taxable income as part of their salary.

The grant value is calculated at the stock price on the grant date. If the stock price moves between grant date and vesting date — up or down — the value you actually receive changes accordingly.

The standard vesting schedule

A very common vesting schedule is vesting over 4 years, with a 1-year cliff. This means you get 0% vesting for the first 12 months, 25% vesting at the 12th month, and 1/48th more vesting each month until the 48th month.

In practice for most tech sales offers, modeled the way this comparator models it:

• Year 1: $0 in equity (cliff year — you must stay 12 months to receive anything)
• Year 2: 25% of grant vests
• Year 3: 25% vests
• Year 4: 25% vests

The cliff is the most important risk in any equity offer: if you leave — voluntarily or involuntarily — before the 12-month mark, you receive zero equity regardless of how much the stock has moved.

The critical difference: public vs. pre-IPO equity

Public company RSUs vest into shares you can sell immediately on the open market. The value is real, liquid, and calculable at any moment.

Pre-IPO RSUs vest into shares of a private company you cannot sell until a liquidity event — an IPO, acquisition, or tender offer. The shares may be worth exactly what the grant said, several times more if the IPO goes well, or $0 if the company never reaches a liquidity event.

Tender offers — where existing employees can sell shares to secondary buyers before an IPO — are becoming more common: Carta recorded 396 tender offers in 2024, up 62% year over year, as founders and employees sought liquidity without going public.

The comparator models both scenarios. For pre-IPO offers, the slider runs from $0 (no liquidity event) upward, so you can see exactly how good the IPO needs to be for the equity to beat the higher OTE.

The Math: Why a Higher Equity Grant Doesn't Always Win

The OTE compounding problem

The most common mistake reps make when evaluating equity offers is comparing the grant value to the OTE difference in isolation. A large equity grant looks much bigger than a modest OTE difference — until you account for time.

A $30,000 OTE difference, compounded over 4 years at 100% attainment, is $120,000 in guaranteed cash. A $400,000 equity grant is $400,000 in potential value — but only if the stock price stays flat or goes up, only if you stay through vesting, and only if the equity is liquid.

Example — a higher-OTE offer vs. an equity-heavy offer:

At flat stock price (Offer B's equity valued at grant price):

At this valuation, Offer B wins by $180,000 over 4 years — but only from Year 2 onward. In Year 1, Offer A pays $30,000 more because the equity cliff means zero equity income in year 1.

The cliff year problem

Year 1 almost always favors the higher OTE offer, because almost all equity grants include a 1-year cliff. The rep receives no equity income in the first 12 months regardless of which company they're at. During that year, the OTE difference is pure cash advantage for the higher-OTE offer.

This matters more than most reps realize at offer time. If the role doesn't work out in the first 6 months — a poor fit, a restructure, a territory change — the rep who took the equity offer loses the entire equity component and got paid less cash. The higher-OTE offer has no such downside in the first year.

Equity vs. OTE: The Decision Framework

When equity usually wins

• The company is late-stage pre-IPO with high conviction on liquidity. Companies at Series D+ with well-known investors and clear IPO timelines represent a very different risk profile than a Series B startup.
• The equity grant is 3× or more of the OTE difference over the vesting period. If the OTE difference is $80,000 over 4 years and the equity grant is $400,000, the equity only needs to hold 20% of its grant value to break even.
• You have strong conviction on stock appreciation.
• You plan to stay for the full vesting period. Leaving at 2 years means you've received roughly half the grant; leaving at 3 years, roughly three-quarters. The math only works if you stay.

When the higher OTE usually wins

• The equity is early-stage pre-IPO with an uncertain timeline. Vested pre-IPO shares you can't sell aren't cash — they're paper.
• You have a high OTE attainment rate and quota is realistic.
• The OTE difference is large relative to the equity grant.
• You have near-term financial obligations. Cash pays rent, covers childcare, services debt.

Enter both offers in the comparator above to see exactly where your break-even sits. The framework above tells you what to look for — your numbers tell you the answer.

How to Evaluate Pre-IPO Equity

Pre-IPO equity requires a different mental model than public company RSUs. The grant value printed in your offer letter is the company's internal 409A valuation — not the market price, not what investors paid, and not what you'll receive at IPO. Private companies set a 409A valuation that is typically lower than the price investors paid in the last funding round, reflecting an illiquidity discount.

When evaluating pre-IPO equity, the question isn't "what is this worth at the 409A price?" — it's "what will this be worth at IPO, and what's the probability of getting there?"

Use the comparator's pre-IPO slider to model three scenarios:

Bear case (no liquidity event): Set the slider to $0. This is always a real possibility.

Base case (IPO at current investor round valuation): Set the slider near the reference valuation you entered at grant.

Bull case (strong IPO or acquisition): Set the slider to several times the reference valuation.

The break-even point — where pre-IPO equity equals the value of the higher-OTE alternative — tells you what valuation you need to come out ahead.

The Vesting Cliff: The Risk Nobody Talks About at Offer Time

If your equity award has a one-year cliff and you only work for the company for 11 months, you would not get anything, since you haven't vested in any part of your award. This single fact deserves more attention than it typically gets during offer negotiations, and it matters specifically for sales reps because:

• Sales roles have higher turnover than most corporate jobs. A territory change, a new manager, a restructure, or a missed quota leading to a PIP can end a role within the first year.
• The first year is the highest-risk year in any new sales role. You're building pipeline from scratch, learning the product, establishing relationships.
• The cliff creates asymmetric risk. Taking a lower OTE for equity means accepting lower cash compensation in Year 1. If you don't clear the cliff, you've taken lower cash with zero equity upside.

The comparator's Year 1 row shows you this cost explicitly.

How RSUs Are Taxed: What You Actually Take Home

All figures in the comparator are pre-tax. When RSUs vest, the fair market value of the shares on the vest date is treated as ordinary income — added to your W-2 alongside salary and commission, taxed at your marginal rate, not a special rate. Employers withhold at the federal supplemental wage rate: 22% on supplemental wages up to $1 million, and 37% above that, per IRS Publication 15.

The key implication: if your total income pushes you into the 32% or 35% bracket, the 22% withholding on RSU vests is insufficient — you'll owe the difference at filing.

For comparing two offers, the relevant point is simple: RSU income and commission income are both taxed as ordinary income. A dollar of vested RSU is taxed the same as a dollar of OTE commission, so the pre-tax comparison in the comparator is a valid basis for comparing the two offers.

Methodology

The comparator calculates the number of RSUs by dividing the grant value by the stock price at grant. Equity income per year is calculated by multiplying the number of RSUs vesting that year by the current slider price. Total compensation per year is OTE plus equity income vested that year.

For pre-IPO offers, the stock price at grant is the 409A valuation provided in the offer letter, and the IPO valuation slider implies a value by applying the same multiplier to the grant-date valuation you enter. This is a simplification that assumes uniform share price appreciation from grant date to IPO, without modeling dilution from new funding rounds.

OTE is used at 100% attainment as the baseline. The standard 4-year vest with 1-year cliff is the default; a 3-year alternative is available in the wizard. All figures are pre-tax.

Assumptions

• OTE is calculated at 100% of quota attainment.
• The standard 4-year vest with 1-year cliff applies unless a 3-year schedule or no-cliff option is selected.
• Stock price or IPO valuation is assumed to apply uniformly to all vesting tranches.
• For pre-IPO offers, the comparator does not model future dilution from additional funding rounds.
• Equity refreshers are not modeled.
• The comparator assumes full vesting — the rep stays through the entire schedule. Leaving early reduces equity income proportionally.
• Pre-IPO equity has no guaranteed value. The $0 scenario is always possible and is represented by the leftmost position of the IPO valuation slider.

Limitations

The comparator models the two most common equity structures in tech sales compensation: public company RSUs and pre-IPO RSUs. It does not model stock options (ISOs or NSOs), employee stock purchase plans (ESPPs), phantom equity, profits interests, or carried interest. It does not model the tax impact of RSU vesting — all figures are pre-tax. It does not account for future dilution from new funding rounds or secondary share issuances in pre-IPO scenarios. Equity refreshers are not included. The break-even calculation assumes flat OTE across all years — if OTE changes due to quota adjustments, promotions, or territory changes, the actual break-even will differ.

This tool is part of RepMath's collection of free sales tools built for B2B sales professionals.

Last updated: 2026-07-20 · Data sources version: 2026